For Patients

Orphan Technologies is developing OT-58 for the treatment of Homocystinuria, and OT-15 for the treatment of Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE). Both OT-58 and OT-15 are innovative enzyme replacement therapies that aim to correct the underlying cause of the diseases by externally providing the active version of the missing enzyme, thereby representing a potentially ideal therapy for these devastating diseases. Orphan Technologies is committed to bringing these innovative medicines to patients.

To keep up-to-date on our clinical progress with these programs please sign up for OT-58 and/or OT-15 e-mail alerts.

Please send me information about the following program(s):
 OT-58, Homocystinuria program OT-15, MNGIE program

Please send me information about:
 Information and updates on clinical studies Participation in patient advisory groups Educational materials

Full Name *

E-mail *

Country *

I have read and understand the Privacy Policy
 I confirm that I have read and understand the privacy policy